重型颅脑创伤中CXCR7、CXCR4及其配体的表达谱
该研究分析了12例重型颅脑创伤患者手术切除的灶周组织与20例正常尸检脑组织中CXCR4、CXCR7及其配体CXCL11、CXCL12的表达。结果显示创伤组两种受体及配体基因表达均升高,鉴别TBI与对照的AUC为0.85–0.98(P<0.001),且趋化因子表达上调者随访至6个月有临床转归良好趋势。
要点
- TBI灶周组织中CXCR4、CXCR7及配体CXCL11、CXCL12基因表达较正常脑组织升高。
- 上述指标区分TBI与正常对照的AUC为0.85–0.98(P<0.001)。
- 趋化因子表达上调患者随访至6个月呈临床转归良好趋势。
核心结论
- CXCR4、CXCR7、CXCL11和CXCL12在TBI中呈现神经保护趋势,值得扩大样本进一步研究其信号通路以开发新治疗策略。
研究设计与样本
- 研究纳入12例接受手术治疗的重型TBI患者的灶周组织,以及20例正常尸检脑组织作为对照。
- 采用实时定量聚合酶链反应分析表达谱,并用免疫组化分析CXCR7和CXCR4蛋白表达,结果与临床演变进行相关性分析。
主要发现
- 与对照相比,TBI组织中两种受体及其配体的基因表达均升高,区分TBI与正常对照的曲线下面积为0.85至0.98(P<0.001)。
- 在TBI中,CXCR7表达与CXCR4及两种配体的表达高度相关。
- TBI样本的神经元和内皮细胞中CXCR7和CXCR4免疫反应较对照增强。
- 趋化因子表达水平上调的患者在随访至6个月时呈现临床转归良好的趋势。
临床怎么用
- CXCR4、CXCR7、CXCL11和CXCL12可作为TBI潜在可成药靶点,但当前证据仅来自小样本探索性分析,尚不能指导临床决策。
局限性
- 样本量小(12例TBI组织与20例对照),作者指出需更多患者研究涉及的信号通路。
- TBI组织为手术切除的灶周组织,对照为尸检正常脑组织,存在来源差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Traumatic brain injury (TBI) is a health problem worldwide, and therapeutic strategies to enhance brain tissue repair to lessen neurologic sequels are imperative. We aimed to analyze the impact of the inflammatory process in TBI through CXCR4 and CXCR7 chemokine receptors and their ligands' CXCL11 and CXCL12 expression profile in search for potential new druggable targets. METHODS: Twelve pericontusional tissues from severe TBI patients submitted to surgical treatment, and 20 control brain tissues from normal autopsy were analyzed for expression profile by real-time quantitative-polymerase chain reaction. CXCR7 and CXCR4 protein expressions were analyzed by immunohistochemistry. The findings were correlated with the clinical evolution. RESULTS: Increased gene expression of both receptors and their ligands was observed in TBI compared with controls, presenting high sensitivity and specificity to differentiate TBI from normal control (area under the curve ranging from 0.85 to 0.98, P < 0.001). In particular, CXCR7 expression highly correlated with CXCR4 and both ligands' expressions in TBI. Higher immunoreactions for CXCR7 and CXCR4 were identified in neurons and endothelial cells of TBI samples compared with controls. The patients presenting upregulated chemokine expression levels showed a trend toward favorable clinical evolution at up to 6 months of follow-up. CONCLUSIONS: The neuroprotective trend of CXCR4, CXCR7, CXCL11, and CXCL12 in TBI observed in this initial analysis warrants further studies with more patients, analyzing the involved signaling pathways for the development of new therapeutic strategies for TBI.
引用
- Mousessian AS, Nunes da Silva CP, Oba-Shinjo SM, et al. CXCR7, CXCR4, and Their Ligand Expression Profile in Traumatic Brain Injury. World Neurosurg. 2020. PMID: 33189916. doi:10.1016/j.wneu.2020.11.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。